Compare Domino's Pizza, Inc. (DPZ) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Illumina, Inc. — how do they compare? Domino's Pizza, Inc. trades at $309.23 (market cap $10.21B), while Illumina, Inc. trades at $278 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 3.9× Domino's Pizza, Inc.'s market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Illumina, Inc. for 83 Days on average.
| DPZ | ILMN | |
|---|---|---|
Market Cap | $10.21B | $39.95B |
Volume | 916,737 | 3,169,503 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $293.69 |
52-Week Low | $282.89 | $91.00 |
Typical Hold Time | 106 Days | 83 Days |
Enterprise Value | $15.17B | $41.31B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $309.02, up 1.95% with a bullish technical signal despite recent earnings misses. The company maintains strong fundamentals with $4.94B revenue, 11.86% net margin, and positive cash flow trends. Recent news highlights dividend stability concerns amid high debt levels and store closures, while analyst consensus remains positive with a $373 price target representing 21% upside potential.
DPZ presents a value opportunity with reasonable valuation (P/E 17.5) but faces execution risks from consecutive earnings misses and substantial debt burden. The stock's 28% YTD decline creates potential for recovery if Q3 earnings beat expectations, though competitive pressures and franchisee challenges require monitoring for sustained growth.
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
